Alliance for Safe Biologic Medicines – Capitol Hill Biosimilars Forum, Washington, D.C.

On February 27, 2012, the Alliance for Safe Biologic Medicines and Bloomberg Government hosted a lunch time Biosimilars Forum on Capitol Hill to discuss the FDA’s draft guidance documents on biosimilar product development.

Panelists included:

Brian Rye, Health-Care Financial Analyst with Bloomberg Government (moderator)
Dr. Richard Dolinar, Chairman of the Alliance for Safe Biologic Medicines
Dr. David Charles, Chief Medical Officer, Vanderbilt Neuroscience Institute, Chairman of the Alliance for Patient Access, and ASBM member partner
Seth Ginsberg, Co-Founder and President of the Global Health Living Foundation, and ASBM member partner
Andrew Spiegel, CEO and co-founder of the Colon Cancer Alliance, and ASBM member partner
Martha Raymond, Patient Advocate, Colon Cancer Alliance
Jeffrey P. Kushan, Partner, Sidley-Austin LL

For audio of the event see below:

Brian Rye
1. Introduction of Ginsberg, Spiegel, & Raymond Audio
2. Introduction of Richard Dolinar, & David Charles Audio
Dr. Richard Dolinar Audio
Dr. David Charles Audio
Seth Ginsberg Audio
Andrew Speigel Audio
Martha Raymond Audio
Jeffrey P. Kushan Audio

Latest News

March 2024 Newsletter

Biden Administration HHS Budget Would Permit Third-Party Substitution of All Biosimilars On March 11th, the Biden Administration released its FY25 HHS Budget. In response, ASBM Executive Director Michael Reilly published a blog post sharing his concerns with the Administration’s proposal to permit widespread automatic (pharmacy-level) substitution of all biosimilars in place of their reference products; without physician approval […]

February 2024 Newsletter

ASBM Joins ICAN, other Patient Advocacy Organizations to Oppose Government Use of “March In Rights” In February, ASBM joined 33 other patient advocacy organizations led by the International Cancer Advocacy Network (ICAN) in a letter to U.S. Congressional leadership, urging them to oppose the use of “march-in rights” to break pharmaceutical patents for drugs developed with […]

ASBM Releases Fact Sheet on Emerging Challenges to Interchangeable Biosimilars Policy

On January 31st, ASBM released a fact sheet describing a variety of proposed policy changes at the state and federal level which would weaken the interchangeable biosimilar standard, or circumvent the patient protections it provides. These include new bills and regulations at the federal level, as well as state legislation and proposals which threaten to […]